<code id='D4C7803603'></code><style id='D4C7803603'></style>
    • <acronym id='D4C7803603'></acronym>
      <center id='D4C7803603'><center id='D4C7803603'><tfoot id='D4C7803603'></tfoot></center><abbr id='D4C7803603'><dir id='D4C7803603'><tfoot id='D4C7803603'></tfoot><noframes id='D4C7803603'>

    • <optgroup id='D4C7803603'><strike id='D4C7803603'><sup id='D4C7803603'></sup></strike><code id='D4C7803603'></code></optgroup>
        1. <b id='D4C7803603'><label id='D4C7803603'><select id='D4C7803603'><dt id='D4C7803603'><span id='D4C7803603'></span></dt></select></label></b><u id='D4C7803603'></u>
          <i id='D4C7803603'><strike id='D4C7803603'><tt id='D4C7803603'><pre id='D4C7803603'></pre></tt></strike></i>

          Home / knowledge / leisure time

          leisure time


          leisure time

          author:entertainment    Page View:1
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In